Abderrahim Oukessou

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · The Lancet Oncology · 2021 · 1.4K citations

Medicine, Oncology, Pharmacology +14

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto et al. · The Lancet · 2021 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +14

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA

Thomas John, Hiroshi Sakai, Satoshi Ikeda et al. · International Journal of Clinical Oncology · 2022 · 32 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study

Mauricette Michallet, Michel Tulliez, Sélim Corm et al. · Current Medical Research and Opinion · 2009 · 24 citations

Medicine, Hematology, Pharmacotherapy +13

Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153

David Waterhouse, Leora Horn, Craig H. Reynolds et al. · Cancer Chemotherapy and Pharmacology · 2018 · 19 citations

Pharmacy, Pharmacokinetics, Pharmacology +11